Copanlisib Dihydrochloride is Used for treating relapsed follicular lymphoma in adult patients who have not responded to at least two prior systemic therapies. It was first introduced by Bayer Healthcare Pharmaceuticals Inc in its drug Aliqopa on Sep 14, 2017.

Copanlisib Dihydrochloride Patents

Given below is the list of patents protecting Copanlisib Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Aliqopa	US10383876	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts	Mar 29, 2032	Bayer Healthcare
Aliqopa	US7511041	Fused azole-pyrimidine derivatives	May 13, 2024 (Expired)	Bayer Healthcare
Aliqopa	US8466283	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis	Oct 22, 2029	Bayer Healthcare
Aliqopa	US9636344	Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts	Mar 29, 2032	Bayer Healthcare
Aliqopa	USRE46856	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis	Oct 22, 2029	Bayer Healthcare

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳